Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts

Aging Cell

Volumn 13, Issue 3, 2014, Pages 573-575

  Saha, Bidisha ^a   Cypro, Alexander ^a   Martin, George M ^a   Oshima, Junko ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autophagy; DNA damage; Mammalian target of rapamycin; Rapamycin; Werner syndrome

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; WERNER SYNDROME PROTEIN; EXODEOXYRIBONUCLEASE; RECQ HELICASE; WRN PROTEIN, HUMAN;

ARTICLE; AUTOPHAGY; CELL GROWTH; CONTROLLED STUDY; DNA DAMAGE; FIBROBLAST; GROWTH RATE; HUMAN; HUMAN CELL; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; WERNER SYNDROME; CELL CYCLE; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY;

MAMMALIA;

CELL CYCLE; CELL GROWTH PROCESSES; DNA DAMAGE; EXODEOXYRIBONUCLEASES; FIBROBLASTS; HUMANS; RECQ HELICASES; SIROLIMUS; WERNER SYNDROME;

EID: 84901423025     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12190     Document Type: Article

References (12)

1. Bae H, Guan JL (2011) Suppression of autophagy by FIP200 deletion impairs DNA damage repair and increases cell death upon treatments with anticancer agents. Mol. Cancer Res. 9, 1232-1241.
2. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS (2011) Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci. Transl. Med. 3, 89ra58.
3. Davis T, Baird DM, Haughton MF, Jones CJ, Kipling D (2005) Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor. J. Gerontol. A Biol. Sci. Med. Sci. 60, 1386-1393.
4. Demidenko ZN, Blagosklonny MV (2008) Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 7, 3355-3361.
5. Hasty P, Sharp ZD, Curiel TJ, Campisi J (2013) mTORC1 and p53: clash of the gods? Cell Cycle 12, 20-25.
6. Johnson SC, Rabinovitch PS, Kaeberlein M (2013) mTOR is a key modulator of ageing and age-related disease. Nature 493, 338-345.
7. Oshima J, Martin GM, Hisama FM (2013). Werner Syndrome. In GeneReviews (Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, eds). Seattle, WA: University of Washington. [WWW document] URL http://ncbi.nlm.nig.gov/pubmed/20301687 [accessed on 18 December 2013]
8. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, MacKay VL, An EH, Strong R, Ladiges WC, Rabinovitch PS, Kaeberlein M, Kennedy BK (2012) Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci. Transl. Med. 4, 144ra103.
9. Rossi ML, Ghosh AK, Bohr VA (2010) Roles of Werner syndrome protein in protection of genome integrity. DNA Repair (Amst) 9, 331-344.
10. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 5, e9979.
11. Szekely AM, Bleichert F, Numann A, Van Komen S, Manasanch E, Ben Nasr A, Canaan A, Weissman SM (2005) Werner protein protects nonproliferating cells from oxidative DNA damage. Mol. Cell. Biol. 25, 10492-10506.
12. Talaei F, van Praag VM, Henning RH (2013) Hydrogen sulfide restores a normal morphological phenotype in Werner syndrome fibroblasts, attenuates oxidative damage and modulates mTOR pathway. Pharmacol. Res. 74, 34-44.